Get The Spin Brief
CRISPRMRIimmunotherapyclinical trialorganoidsbiological age
Pipeline tracker

CTX112 (zugocabtagene geleucel)

Phase 1Evidence reviewed by an editor
CTX112 (zugocabtagene geleucel)CRISPR Therapeutics · Autoimmune diseases incl. systemic lupus erythematosus and systemic sclerosis
Phase 1 · Allogeneic CRISPR-edited CD19 CAR-T cell therapyAs of Sep 25, 2026

As of the company's Aug. 3, 2026 update, CTX112 is in Phase 1 basket trials across several autoimmune diseases (company release).

As of the company's Aug. 3, 2026 update, CTX112 is in Phase 1 basket trials across several autoimmune diseases (company release).

What this stage means

Phase 1 trials are the first tests in people, mainly checking safety and dose in small groups.

A development stage describes where the evidence stands for one specific use. It does not mean the product works for everyone, is available everywhere, or will succeed commercially.

Development stages, sourced

Elsewhere in the pipeline

Selected therapies and technologies at every stage, from preclinical research to approval. Each stage is dated and linked to a primary source.

Full tracker
Casgevy (exagamglogene autotemcel)Vertex Pharmaceuticals and CRISPR Therapeutics · Sickle cell disease and transfusion-dependent beta thalassemia
Approved/cleared · CRISPR/Cas9-edited autologous stem-cell therapyAs of Sep 25, 2026
Intismeran autogene (V940 / mRNA-4157)Moderna and Merck · High-risk resected melanoma (with pembrolizumab)
Phase 3 · Individualized neoantigen mRNA cancer vaccineAs of Sep 25, 2026
da Vinci 5 surgical system — cardiac indicationsIntuitive Surgical · Cardiac procedures incl. mitral valve repair
Approved/cleared · Robotic-assisted surgical systemAs of Sep 25, 2026
Galleri multi-cancer early detection testGRAIL · Multi-cancer screening in adults 50+
Under review · Cell-free DNA methylation blood test (NGS + machine learning)As of Sep 25, 2026
Optive AI software for Swoop portable MRIHyperfine · Point-of-care brain imaging
Approved/cleared · AI image-reconstruction software for portable ultra-low-field MRIAs of Sep 25, 2026
Hepatocyte epigenetic reprogramming medicineNewLimit · Age-related liver dysfunction
Preclinical · Epigenetic reprogramming therapyAs of Sep 25, 2026

Stages summarise the most advanced publicly documented status for the named use. “Approved” applies to specific indications and regions only. Nothing here is medical or investment advice.